(VIANEWS) – SCYNEXIS (SCYX), Noah Holdings Limited (NOAH), Trinity Industries (TRN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SCYNEXIS (SCYX)
889.4% sales growth and 132.23% return on equity
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, SCYNEXIS has a trailing twelve months EPS of $1.49.
PE Ratio
SCYNEXIS has a trailing twelve months price to earnings ratio of 1.33. Meaning, the purchaser of the share is investing $1.33 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 132.23%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SCYNEXIS’s EBITDA is -9.96.
Volume
Today’s last reported volume for SCYNEXIS is 95023 which is 62.44% below its average volume of 252990.
Yearly Top and Bottom Value
SCYNEXIS’s stock is valued at $1.98 at 19:22 EST, way under its 52-week high of $3.87 and way above its 52-week low of $1.15.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.1%, now sitting on 135.87M for the twelve trailing months.
2. Noah Holdings Limited (NOAH)
33.2% sales growth and 9.42% return on equity
Noah Holdings Limited, together with its subsidiaries, operates as a wealth and asset management service provider with the focus on investment and asset allocation services for high net worth individuals and enterprises in Mainland of China, Hong Kong, and internationally. It operates through three segments: Wealth Management, Asset Management, and Other Businesses. The company offers investment products, including domestic and overseas publicly raised and public securities investment funds, privately-raised investment funds, and private equity products; customized value-added financial services, such as investor education and trust services, as well as insurance brokerage services; and insurance products. It also provides onshore and offshore private equity, real estate, public securities, multi-strategy, and other investment products, as well as lending services. The company was founded in 2005 and is headquartered in Shanghai, the People's Republic of China.
Earnings Per Share
As for profitability, Noah Holdings Limited has a trailing twelve months EPS of $1.89.
PE Ratio
Noah Holdings Limited has a trailing twelve months price to earnings ratio of 6.65. Meaning, the purchaser of the share is investing $6.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.42%.
Yearly Top and Bottom Value
Noah Holdings Limited’s stock is valued at $12.57 at 19:22 EST, way under its 52-week high of $21.53 and way higher than its 52-week low of $10.88.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 25, 2023, the estimated forward annual dividend rate is 0.38 and the estimated forward annual dividend yield is 2.97%.
Moving Average
Noah Holdings Limited’s value is under its 50-day moving average of $12.91 and way under its 200-day moving average of $14.08.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.6%, now sitting on 3.38B for the twelve trailing months.
3. Trinity Industries (TRN)
11.8% sales growth and 8.7% return on equity
Trinity Industries, Inc. provides rail transportation products and services under the TrinityRail name in North America. It operates in two segments, Railcar Leasing and Management Services Group, and Rail Products Group. The Railcar Leasing and Management Services Group segment leases freight and tank railcars; originates and manages railcar leases for third-party investors; and provides fleet maintenance and management services. As of December 31, 2022, it had a fleet of 108,440 railcars. This segment serves industrial shipper and railroad companies operating in agriculture, construction and metals, consumer products, energy, and refined products and chemicals markets. The Rail Products Group segment manufactures freight and tank railcars for transporting various liquids, gases, and dry cargo; and offers railcar maintenance and modification services. This segment serves railroads, leasing companies, and industrial shippers of products in the agriculture, construction and metals, consumer products, energy, and refined products and chemicals markets. It sells or leases products and services through its own sales personnel and independent sales representatives. Trinity Industries, Inc. was incorporated in 1933 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Trinity Industries has a trailing twelve months EPS of $1.07.
PE Ratio
Trinity Industries has a trailing twelve months price to earnings ratio of 23.85. Meaning, the purchaser of the share is investing $23.85 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.7%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Trinity Industries’s EBITDA is 76.5.
Sales Growth
Trinity Industries’s sales growth is 32.5% for the present quarter and 11.8% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jan 10, 2024, the estimated forward annual dividend rate is 1.12 and the estimated forward annual dividend yield is 4.39%.
4. Euronet Worldwide (EEFT)
9.4% sales growth and 25.61% return on equity
Euronet Worldwide, Inc. provides payment and transaction processing and distribution solutions to financial institutions, agents, retailers, merchants, content providers, and individual consumers worldwide. The company's Electronic Fund Transfer Processing segment provides electronic payment solutions, including automated teller machine (ATM) cash withdrawal and deposit services, ATM network participation, outsourced ATM and point-of-sale (POS) management solutions, credit and debit card outsourcing, card issuing, and merchant acquiring services. It also offers ATM and POS currency conversion, ATM surcharge, advertising, customer relationship management, mobile top-up, bill payment, fraud management, foreign remittance and cardless payout, banknote recycling, and tax-refund services; and integrated electronic financial transaction software solutions, as well as delivers non-cash products. This segment operates a network of 42,713 ATMs and approximately 438,000 POS terminals. Its epay segment distributes and processed prepaid mobile airtime and other electronic payment products; and provides payment processing services for various prepaid products, cards, and services, as well as vouchers and physical gift fulfillment, and gift card distribution and processing services. This segment operates a network of approximately 775,000 POS terminals. The company's Money Transfer segment offers consumer-to-consumer and account-to-account money transfer, customers bill payment, check cashing, foreign currency exchange, mobile top-up, and cash management and foreign currency risk management services, as well as payment alternatives, such as money orders and prepaid debit cards. This segment operates a network of approximately 510,000 money transfer locations. The company was formerly known as Euronet Services, Inc. and changed its name to Euronet Worldwide, Inc. in August 2001. Euronet Worldwide, Inc. was founded in 1994 and is headquartered in Leawood, Kansas.
Earnings Per Share
As for profitability, Euronet Worldwide has a trailing twelve months EPS of $5.38.
PE Ratio
Euronet Worldwide has a trailing twelve months price to earnings ratio of 18.46. Meaning, the purchaser of the share is investing $18.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.61%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 26.6% and 21.8%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.8%, now sitting on 3.6B for the twelve trailing months.
Moving Average
Euronet Worldwide’s worth is above its 50-day moving average of $90.71 and above its 200-day moving average of $96.94.
Volume
Today’s last reported volume for Euronet Worldwide is 49249 which is 88.07% below its average volume of 412975.
5. ICON plc (ICLR)
6.5% sales growth and 5.97% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $6.22.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 41. Meaning, the purchaser of the share is investing $41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.97%.
Volume
Today’s last reported volume for ICON plc is 626370 which is 17.9% above its average volume of 531270.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.8%, now sitting on 8.02B for the twelve trailing months.
